Impact of possible removal of the Titanium dioxide from human medicines formulations […]
A comparison between CSV Guideline / regulations in Japan, India and China
EU IVDR – Clinical Evidence and Performance Evaluation by Andrea Colombo, MD […]
Pharmacovigilance Data: challenges for Pharmaceutical Companies by: Daniela Rota PV Unit Manager […]
New Annex 1, among other important points considered, dedicates several comments on the importance and the impact of Critical Utilities, involved at different level either because directly impacting on Contamination Control Strategy (CCS) document, or because potential direct or indirect source of bio-contamination of the final product.
New EU GMP Annex 1 – Implications for QRM application by Alessio […]
Covid-19 vaccines supply chain has become a target for cybersecurity attacks. How […]
Smart Working: dealing with IT support implications by Dario Palese Current global […]
We consider the potential risks for Pharma and MD companies keeping their systems running on obsolete Windows versions and a good strategy to get up to date.
Why MD Cybersecurity is so important by Danilo Maruccia, Executive Consultant & […]